Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Technology Innovation stories

Aug 6, 2026

FDA approves Moderna's mFlusiva, first mRNA-based flu vaccine in the United States

The Food and Drug Administration approved Moderna's mFlusiva on Wednesday, marking the first mRNA-based influenza vaccine authorized in the U.S. The vaccine is approved for adults aged 50 and older, representing a significant expansion of mRNA technology beyond COVID-19 vaccines.

Aug 6, 2026·6 sources
00

Top claims

  • ▪Moderna agreed to run a postmarketing clinical trial in adults ages 65 and older to confirm mFlusiva's clinical benefit as a condition of its accelerated approval
  • ▪Moderna's mRNA-based flu vaccine requires two to three months from strain selection to rollout, compared to approximately six months for traditional egg-based vaccines
  • ▪In a smaller study of adults aged 65 and older, mFlusiva generated a strong protective immune response compared to an existing high-dose flu vaccine

Subtopics

Drug Approval and Clinical Trials1Drug Policy, Pricing & Approval1FDA drug approval1MRNA vaccine technology1Public healthcare1Vaccine development and innovation1Vaccines and Immunization Policy1

Related timelines

Congress

110 stories

Crypto hacks

100 stories

Iran War

209 stories

Strait of Hormuz blockage

148 stories

Trump administration

161 stories